Risk of acute coronary syndrome in elderly users of antipsychotic drugs: A nested case-control study

Heart

Volumn 98, Issue 15, 2012, Pages 1166-1171

  Kleijer, Bart C ^a,b   Koek, Huiberdina L ^b   Van Marum, Rob J ^b,c   Jansen, Paul A F ^b   Egberts, Toine C G ^b,d   Heerdink, Eibert R ^b,d  

^a GeriMedica Medical Practice for Frail Elderly   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^c JEROEN BOSCH HOSPITAL   (Netherlands)

^d UTRECHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT;

ACUTE CORONARY SYNDROME; ADULT; AGE; AGED; ARTICLE; CARDIOVASCULAR RISK; CASE CONTROL STUDY; COHORT ANALYSIS; COMORBIDITY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EXPOSURE; DRUG USE; FEMALE; GENDER; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; PRESCRIPTION; PRIORITY JOURNAL; REGISTRATION;

ACUTE CORONARY SYNDROME; AGE FACTORS; AGED; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; FEMALE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; NETHERLANDS; PROGNOSIS; PSYCHOTIC DISORDERS; RISK ASSESSMENT; RISK FACTORS; SEX DISTRIBUTION; SURVIVAL RATE;

EID: 84863786915     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-301801     Document Type: Article

References (63)

1. FDA. Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Washington, DC: Department of Health and Human Services, 2005.
2. Schneider LS, Dagerman K, Insel PS. Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006;14:191-210.
3. Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005;294:1934-43. (Pubitemid 41464695)
4. Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007;176:627-32. (Pubitemid 46426056)
5. Canoso RT, de Oliveira RM, Nixon RA. Neuroleptic-associated autoantibodies. A prevalence study. Biol Psychiatry 1990;27:863-70. (Pubitemid 20145673)
6. Goff DC, Sullivan LM, McEvoy JP, et al. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 2005;80:45-53. (Pubitemid 41587462)
7. Carlson C, Hornbuckle K, DeLisle F, et al. Diabetes mellitus and antipsychotic treatment in the United Kingdom. Eur Neuropsychopharmacol 2006;16:366-75. (Pubitemid 43815731)
8. Daumit GL, Goff DC, Meyer JM, et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008;105:175-87.
9. de Haan L, Booij J, Lavalaye J, et al. Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. Psychopharmacology (Berl) 2006;183:500-5. (Pubitemid 41721152)
10. Taylor DM, McAskill R. Atypical antipsychotics and weight gain-a systematic review. Acta Psychiatr Scand 2000;101:416-32. (Pubitemid 30365564)
11. Nakagawa S, Pedersen L, Olsen ML, et al. Antipsychotics and risk of first-time hospitalization for myocardial infarction: a population-based case-control study. J Intern Med 2006;260:451-8. (Pubitemid 44571133)
12. Brown S. Excess mortality of schizophrenia. A meta-analysis. Br J Psychiatry 1997;171:502-8. (Pubitemid 27527317)
13. Suvisaari J, Perala J, Saarni SI, et al. Coronary heart disease and cardiac conduction abnormalities in persons with psychotic disorders in a general population. Psychiatry Res 2010;175:126-32.
14. Jerrell JM, McIntyre RS. Cerebro- and cardiovascular conditions in adults with schizophrenia treated with antipsychotic medications. Hum Psychopharmacol 2007;22:361-4. (Pubitemid 47316119)
15. Tiihonen J, Lonnqvist J, Wahlbeck K, et al. 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009;374:620-7.
16. Bresee LC, Majumdar SR, Patten SB, et al. Prevalence of cardiovascular risk factors and disease in people with schizophrenia: a population-based study. Schizophr Res 2010;117:75-82.
17. Montout C, Casadebaig F, Lagnaoui R, et al. Neuroleptics and mortality in schizophrenia: prospective analysis of deaths in a French cohort of schizophrenic patients. Schizophr Res 2002;57:147-56. (Pubitemid 35240016)
18. Jakobsen AH, Foldager L, Parker G, et al. Quantifying links between acute myocardial infarction and depression, anxiety and schizophrenia using case register databases. J Affect Disord 2008;109:177-81. (Pubitemid 351707704)
19. McDermott S, Moran R, Platt T, et al. Heart disease, schizophrenia, and affective psychoses: epidemiology of risk in primary care. Community Ment Health J 2005;41:747-55. (Pubitemid 41674452)
20. Curkendall SM, Mo J, Glasser DB, et al. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry 2004;65:715-20.
21. Blasco-Fontecilla H, Baca-Garcia E, de Leon J. Do atypical antipsychotic drugs reduce the risk of ischemic heart disease and mortality? Possible role of 5-HT2A receptor blockade. Schizophr Res 2010;119:160-3.
22. Weinmann S, Read J, Aderhold V. Influence of antipsychotics on mortality in schizophrenia: systematic review. Schizophr Res 2009;113:1-11.
23. Raedler TJ. Cardiovascular aspects of antipsychotics. Curr Opin Psychiatry 2010;23:574-81.
24. Allender S, Scharbotough P, Peto V, et al. European Cardiovascular Disease Statistics. United Kingdom: British Heart Foundation, 2009. (2008 Ed.).
25. Rapoport M, Mamdani M, Shulman KI, et al. Antipsychotic use in the elderly: shifting trends and increasing costs. Int J Geriatr Psychiatry 2005;20:749-53. (Pubitemid 41158720)
26. Barak Y, Baruch Y, Mazeh D, et al. Cardiac and cerebrovascular morbidity and mortality associated with antipsychotic medications in elderly psychiatric inpatients. Am J Geriatr Psychiatry 2007;15:354-6.
27. Huybrechts KF, Rothman KJ, Silliman RA, et al. Risk of death and hospital admission for major medical events after initiation of psychotropic medications in older adults admitted to nursing homes. CMAJ 2011;183:E411-19.
28. Raivio MM, Laurila JV, Strandberg TE, et al. Neither atypical nor conventional antipsychotics increase mortality or hospital admissions among elderly patients with dementia: a two-year prospective study. Am J Geriatr Psychiatry 2007;15:416-24.
29. Simoni-Wastila L, Ryder PT, Qian J, et al. Association of antipsychotic use with hospital events and mortality among medicare beneficiaries residing in long-term care facilities. Am J Geriatr Psychiatry 2009;17:417-27.
30. Herings RM, Bakker A, Stricker BH, et al. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 1992;46:136-40.
31. WHO. World Health Organisation ATC/DDD Index. http://www.whocc.no/atcddd/ index (accessed 1 Sep 2010).
32. U.S. Department of Health, Human Services. The International Statistical Classification of Diseases, Injuries and Causes of Death. Ninth Revision. Clinical Modification. Washington DC: U.S. Department of health and human Services, 1979.
33. Richelson E. Receptor pharmacology of neuroleptics: relation to clinical effects. J Clin Psychiatry 1999;60(Suppl 10):5-14. (Pubitemid 29237170)
34. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 2000;68:29-39.
35. Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-26.
36. Chapman N, Chen CY, Fujita T, et al. Time to re-appraise the role of alpha-1 adrenoceptor antagonists in the management of hypertension? J Hypertens 2010;28:1796-803.
37. Booth GL, Kapral MK, Fung K, et al. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet 2006;368:29-36. (Pubitemid 43947203)
38. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-73. (Pubitemid 47321908)
39. Enger C, Weatherby L, Reynolds RF, et al. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 2004;192:19-27. (Pubitemid 38101693)
40. Osborn DP, Levy G, Nazareth I, et al. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry 2007;64:242-9. (Pubitemid 46220782)
41. Thorogood M, Cowen P, Mann J, et al. Fatal myocardial infarction and use of psychotropic drugs in young women. Lancet 1992;340:1067-8.
42. Mirandola M, Andretta M, Corbari L, et al. Prevalence, incidence and persistence of antipsychotic drug prescribing in the Italian general population: retrospective database analysis, 1999-2002. Pharmacoepidemiol Drug Saf 2006;15:412-20. (Pubitemid 44018700)
43. Cascade EF, Kalali AH, Citrome L. Antipsychotic use varies by patient age. Psychiatry (Edgmont) 2007;4:20-3.
44. Dietrich-Muszalska A, Rabe-Jablonska J, Nowak P, et al. The first- and secondgeneration antipsychotic drugs affect ADP-induced platelet aggregation. World J Biol Psychiatry 2010;11:268-75.
45. Bertha BG, Sill JC, Berger I, et al. High-dose droperidol protects against experimental coronary thrombosis in dogs and pigs and attenuates aggregation of porcine platelets and Ca2+ mobilization in human platelets. Anesthesiology 1993;78:733-43. (Pubitemid 23110048)
46. Przyklenk K, Frelinger AL, Linden MD, et al. Targeted inhibition of the serotonin 5HT2A receptor improves coronary patency in an in vivo model of recurrent thrombosis. J Thromb Haemost 2010;8:331-40.
47. Davidsen O, Lindeneg O, Walsh M. Analgesic treatment with levomepromazine in acute myocardial infarction. A randomized clinical trial. Acta Med Scand 1979;205:191-4. (Pubitemid 9137346)
48. Strike PC, Perkins-Porras L, Whitehead DL, et al. Triggering of acute coronary syndromes by physical exertion and anger: clinical and sociodemographic characteristics. Heart 2006;92:1035-40. (Pubitemid 44125210)
49. Steptoe A, Strike PC, Perkins-Porras L, et al. Acute depressed mood as a trigger of acute coronary syndromes. Biol Psychiatry 2006;60:837-42. (Pubitemid 44527890)
50. Moller J, Ahlbom A, Hulting J, et al. Sexual activity as a trigger of myocardial infarction. A case-crossover analysis in the Stockholm Heart Epidemiology Programme (SHEEP). Heart 2001;86:387-90. (Pubitemid 32889371)
51. van den Buuse M. Acute effects of antipsychotic drugs on cardiovascular responses to stress. Eur J Pharmacol 2003;464:55-62.
52. Yanagisawa H. Acute myocardial infarction improved by neuroleptic analgesic therapy. South Med J 1990;83:839-42. (Pubitemid 20247201)
53. Denollet J, Brutsaert DL. Reducing emotional distress improves prognosis in coronary heart disease: 9-year mortality in a clinical trial of rehabilitation. Circulation 2001;104:2018-23. (Pubitemid 33027040)
54. Gulliksson M, Burell G, Vessby B, et al. Randomized controlled trial of cognitive behavioral therapy vs standard treatment to prevent recurrent cardiovascular events in patients with coronary heart disease: secondary Prevention in Uppsala Primary Health Care project (SUPRIM). Arch Intern Med 2011;171:134-40.
55. Win S, Parakh K, Eze-Nliam CM, et al. Depressive symptoms, physical inactivity and risk of cardiovascular mortality in older adults: the cardiovascular health study. Heart 2011;97:500-5.
56. Dorr M. Silent myocardial infarction: the risk beyond the first admission. Heart 2010;96:1434-5.
57. Seidel S, Aigner M, Ossege M, et al. Antipsychotics for acute and chronic pain in adults. J Pain Symptom Manage 2010;39:768-78.
58. Wooltorton E. Risperidone (Risperdal): increased rate of cerebrovascular events in dementia trials. CMAJ 2002;167:1269.
59. Wooltorton E. Olanzapine (Zyprexa): increased incidence of cerebrovascular events in dementia trials. CMAJ 2004;170:1395. (Pubitemid 38594631)
60. Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry 2004;65(Suppl 18):36-46.
61. Straus SM, Bleumink GS, Dieleman JP, et al. Antipsychotics and the risk of sudden cardiac death. Arch Intern Med 2004;164:1293-7. (Pubitemid 38828879)
62. Van Noord C, Sturkenboom MC, Straus SM, et al. Non-cardiovascular drugs that inhibit hERG-encoded potassium channels and risk of sudden cardiac death. Heart 2011;97:215-20.
63. Leening MJ, Elias-Smale SE, Felix JF, et al. Unrecognised myocardial infarction and long-term risk of heart failure in the elderly: the Rotterdam Study. Heart 2010;96:1458-62.